History | Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 136 KB)

Published:

26 May 2021
Register of interests (PDF 156 KB)

Published:

26 May 2021

Final draft guidance

Final draft guidance
Final appraisal document (PDF 238 KB)

Published:

20 April 2021
Final appraisal document - managed access agreement (PDF 475 KB)

Published:

20 April 2021
Committee papers (PDF 14.69 MB)

Published:

20 April 2021
Public committee slides (PDF 1.01 MB)

Published:

20 April 2021

Invitation to participate

Final scope (PDF 202 KB)

Published:

26 June 2020
Final stakeholder list (PDF 180 KB)

Published:

26 June 2020
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 342 KB)

Published:

26 June 2020
Equality impact assessment (Scoping) (PDF 129 KB)

Published:

26 June 2020

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 216 KB)

Published:

07 May 2020
Draft matrix post referral (PDF 179 KB)

Published:

07 May 2020